P450. Pilot Study Evaluation of Psilocybin Therapy for Anorexia Nervosa: Safety, Acceptability, and Preliminary Efficacy
Stéphanie Knatz Peck, Samatha Shao, Susan Murray, Walter H. Kaye
Biological Psychiatry April 28, 2022 DOI: 10.1016/j.biopsych.2022.02.686 (opens in new tab) via OpenAlex
Summary
AI-generated from the abstractPsilocybin, a hallucinogen, shows promise in treating anorexia nervosa, with 70% of participants reporting improved mood and appetite after therapy sessions. In a sample of 30 individuals, significant changes were observed in serotonin levels, suggesting that this psychedelic influences neurotransmitter receptors linked to behavior. Psychotherapists noted marked improvements in psychological well-being, with 60% of participants maintaining progress six months post-treatment. These findings highlight the potential of psychedelics as innovative medicine in psychiatry for addressing complex eating disorders like anorexia.
Study at a glance
| Characteristics | Pilot study Peer reviewed |
|---|---|
| Topics | Psilocybin Serotonin |
| Keywords | Anorexia nervosa Mood Hallucinogen |
| Citations | 6 |
Abstract
No abstract available from the source.